ReviewNeural regeneration research2023
Agomelatine: a potential novel approach for the treatment of memory disorder in neurodegenerative disease.
Review in Neural regeneration research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.
- Effects of Agomelatine on Sleep Across Populations: A Systematic Review and Meta-Analysis.Journal of sleep research · 2026Pooled it
- Agomelatine ameliorates abortion-related alterations in rats: Insights from behavioural, biochemical and histological analyses.Experimental physiology · 2026Article
- Circadian rhythms and chronotherapy in Alzheimer's disease: Mechanisms and therapeutic implications.Neuroprotection (Chichester, England) · 2026Review
- Cytoprotective Effects of Agomelatine on Hepatic Ischemia-Reperfusion Injury in a Rat Model.International journal of molecular sciences · 2026Article
- Agomelatine Ameliorates Cognitive and Behavioral Deficits in Aβ-Induced Alzheimer's Disease-like Rat Model.Medicina (Kaunas, Lithuania) · 2025Article
- A new horizon for neuroscience: terahertz biotechnology in brain research.Neural regeneration research · 2025Article
- Agomelatine Is Unable to Attenuate Kainic Acid-Induced Deficits in Early Life Communicative Behavior.Developmental psychobiology · 2024Article
- A multicenter retrospective study of antidepressant use in outpatient clinics in China pre- and post-COVID.International journal of clinical pharmacy · 2024Article
- Chronic Caffeine Consumption, Alone or Combined with Agomelatine or Quetiapine, Reduces the Maximum EEG Peak, As Linked to Cortical Neurodegeneration, Ovarian Estrogen Receptor Alpha, and Melatonin Receptor 2.Psychopharmacology · 2024Article
- Potential biomarkers and therapeutic targets for obsessive compulsive disorder: Evidences from clinical studies.Biochemia medica · 2024Review
- Changes in Melatonin Concentration in a Clinical Observation Study under the Influence of Low-Frequency Magnetic Fields (Magnetic Stimulation in Men with Low Back Pain)-Results of Changes in an Eight-Point Circadian Profile.International journal of molecular sciences · 2023Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Agomelatine is a selective agonist of melatonin receptor 1A/melatonin receptor 1B (MT
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.